BENGALURU -- Indian drugmaker Sun Pharma said on Monday that it will fork out $11.75 billion in cash to buy U.S.-based Organon, underscoring a broader push by pharmaceutical companies in the South Asian nation to diversify beyond low-value generics to cement their footprint in international markets.